IL149524A0 - HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS - Google Patents

HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS

Info

Publication number
IL149524A0
IL149524A0 IL14952400A IL14952400A IL149524A0 IL 149524 A0 IL149524 A0 IL 149524A0 IL 14952400 A IL14952400 A IL 14952400A IL 14952400 A IL14952400 A IL 14952400A IL 149524 A0 IL149524 A0 IL 149524A0
Authority
IL
Israel
Prior art keywords
hmg
coa reductase
extended release
release formulations
reductase inhibitor
Prior art date
Application number
IL14952400A
Original Assignee
Andrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Corp filed Critical Andrx Corp
Publication of IL149524A0 publication Critical patent/IL149524A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14952400A 1999-11-08 2000-11-03 HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS IL149524A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43557699A 1999-11-08 1999-11-08
PCT/US2000/030415 WO2001034123A1 (en) 1999-11-08 2000-11-03 Hmg-coa reductase inhibitor extended release formulation

Publications (1)

Publication Number Publication Date
IL149524A0 true IL149524A0 (en) 2002-11-10

Family

ID=23728948

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14952400A IL149524A0 (en) 1999-11-08 2000-11-03 HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS

Country Status (8)

Country Link
AU (1) AU768950B2 (en)
CA (1) CA2390301A1 (en)
DE (1) DE10085183T1 (en)
GB (1) GB2371748B (en)
HK (1) HK1050134A1 (en)
IL (1) IL149524A0 (en)
NZ (1) NZ518770A (en)
WO (1) WO2001034123A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490029A4 (en) * 2002-03-22 2006-02-22 Ranbaxy Lab Ltd Controlled release drug delivery system of pravastatin
MXPA05002074A (en) * 2002-09-03 2005-06-08 Biovail Lab Int Srl Pharmaceuticals formulations and methods for modified release of statin drugs.
WO2006054307A2 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
EP2079448A2 (en) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
EP2967060A4 (en) 2013-03-15 2016-11-23 Cedars Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
EP3179983A4 (en) 2014-08-13 2018-01-10 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
IN176897B (en) * 1993-10-29 1996-09-28 Cadila Lab Ltd
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device

Also Published As

Publication number Publication date
HK1050134A1 (en) 2003-06-13
AU768950B2 (en) 2004-01-08
CA2390301A1 (en) 2001-05-17
GB2371748A (en) 2002-08-07
DE10085183T1 (en) 2002-10-24
WO2001034123A1 (en) 2001-05-17
AU1360701A (en) 2001-06-06
GB0210619D0 (en) 2002-06-19
NZ518770A (en) 2004-02-27
GB2371748B (en) 2004-12-01

Similar Documents

Publication Publication Date Title
AP2002002409A0 (en) Pharmaceutical compositions comprising a hmg reductase inhibitor
GB9900416D0 (en) Inhibitors
AU3368400A (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease
AU1530001A (en) Inhibitor compositions
EP1286702A4 (en) HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS
AU2001264264A1 (en) Sustained release compositions
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
HK1047276A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
IL132786A0 (en) Hmg-coa reductase inhibitor preparation process
IL149524A0 (en) HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS
AU3235100A (en) Prothease inhibitors
AU2001280461A1 (en) Substituted pyrrole compounds and their use as spla2 inhibitors
GB2389113B (en) B-secretase inhibitor
AU5762899A (en) Caspase inhibitor
AU2001269121A1 (en) Substituted amidoalkyl-uracils as parp inhibitors
HUP0105145A3 (en) Process for producing hmg-coa reductase inhibitor
HUP0201597A2 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
GB9911546D0 (en) Release of poorly soluble agents
HUP0301728A3 (en) Hmg-coa reductase inhibiting pharmaceutical compositions and their use
AU2001228647A1 (en) Dihydrofolate reductase inhibitors
HK1077230A1 (en) Medicinal composition hmg-coa reductase inhibitor
AU1548801A (en) Melanogenesis inhibitor
AU2002400A (en) Telomerase inhibitors
AUPQ318099A0 (en) Impact inhibitor